Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp is poised for positive growth driven by several key factors, including an anticipated increase in iDose revenue estimates by 3.5% to 5.9% from FY26 onward due to a rising proportion of repeat administration patients. The company's expanding total addressable market (TAM) through upcoming launches and its pipeline of innovative products suggests significant potential for revenue growth and a path towards profitability in the coming years. Furthermore, Glaukos has demonstrated mid-single digit revenue growth in domestic non-iDose glaucoma products, indicating a solid performance that aligns with broader market trends, and management has highlighted international strength as a promising area for expansion.

Bears say

Glaukos Corporation faces significant headwinds that adversely impact its financial outlook, primarily due to lower-than-expected growth in the minimally invasive glaucoma surgery (MIGS) market and a sluggish adoption of its iDose and iStent infinite products. The competitive landscape continues to intensify with an increasing number of entrants, coupled with potential reimbursement challenges, which may hinder sales execution and adoption rates across its product lines. Additionally, risks surrounding the timely realization of pipeline products and new launches further contribute to uncertainty in Glaukos' growth trajectory.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $133.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $133.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.